Affymax and Takeda aim to submit Hematide to the FDA in 2011

08/5/2010 | Bloomberg Businessweek

Affymax and Japanese partner Takeda Pharmaceutical plan to file for FDA approval of anemia treatment Hematide during the first half of next year. Affymax said it will pursue an application for the treatment of anemia in dialysis patients and continue evaluating the drug's nondialysis use.

View Full Article in:

Bloomberg Businessweek

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Abbott
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA